Compare Gilead Sciences, Inc. (GILD) vs iShares 3 7 Year Treasury Bond ETF (IEI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs iShares 3 7 Year Treasury Bond ETF — how do they compare? Gilead Sciences, Inc. trades at $133.38 (market cap $163.51B), while iShares 3 7 Year Treasury Bond ETF trades at $116.81. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while iShares 3 7 Year Treasury Bond ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| GILD | IEI | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | Fixed Income |
52-Week High | $155.80 | $120.72 |
52-Week Low | $108.22 | $116.45 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
iShares 3-7 Year Treasury Bond ETF (IEI) trades at $116.865, showing minimal daily movement with a 0.11% gain. The technical outlook is bearish, with moving averages signaling downward pressure. The ETF has paid consistent dividends recently, including $0.37 in May 2026 and $0.36 in April 2026. Financial media comparisons highlight IEI's focus on intermediate-term U.S. Treasuries, offering lower volatility than corporate bond alternatives but facing yield competition from broader bond ETFs.
The outlook for IEI is tied to Federal Reserve policy and bond market dynamics. Rising rate hike expectations create headwinds for intermediate-term Treasury ETFs, while inflation concerns may shift investor preference toward inflation-protected securities. The ETF's government debt focus provides safety during market stress but limits yield potential compared to corporate bond funds, presenting a trade-off between stability and income generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →
